Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy
Robert M. Samstein, Chirag Krishna, Xiaoxiao Ma, et al.
Nature Cancer (2020) Vol. 1, Iss. 12, pp. 1188-1203
Open Access | Times Cited: 153

Showing 1-25 of 153 citing articles:

Treatment landscape of triple-negative breast cancer — expanded options, evolving needs
Giampaolo Bianchini, Carmine De Angelis, Luca Licata, et al.
Nature Reviews Clinical Oncology (2021) Vol. 19, Iss. 2, pp. 91-113
Closed Access | Times Cited: 769
The Next Decade of Immune Checkpoint Therapy
Padmanee Sharma, Bilal A. Siddiqui, Swetha Anandhan, et al.
Cancer Discovery (2021) Vol. 11, Iss. 4, pp. 838-857
Open Access | Times Cited: 533
Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends
Qian Sun, Zhenya Hong, Cong Zhang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 228
Improved prediction of immune checkpoint blockade efficacy across multiple cancer types
Diego Chowell, Seong‐Keun Yoo, Cristina Valero, et al.
Nature Biotechnology (2021) Vol. 40, Iss. 4, pp. 499-506
Open Access | Times Cited: 173
Translational advances in pancreatic ductal adenocarcinoma therapy
Abdel Hosein, Stephanie K. Dougan, Andrew J. Aguirre, et al.
Nature Cancer (2022) Vol. 3, Iss. 3, pp. 272-286
Open Access | Times Cited: 170
Ovarian cancer mutational processes drive site-specific immune evasion
Ignacio Vázquez-Garćıa, Florian Uhlitz, Nicholas Ceglia, et al.
Nature (2022) Vol. 612, Iss. 7941, pp. 778-786
Open Access | Times Cited: 147
Tumor heterogeneity reshapes the tumor microenvironment to influence drug resistance
Aiping Zhang, Kai Miao, Heng Sun, et al.
International Journal of Biological Sciences (2022) Vol. 18, Iss. 7, pp. 3019-3033
Open Access | Times Cited: 139
Mechanisms driving the immunoregulatory function of cancer cells
Antoinette van Weverwijk, Karin E. de Visser
Nature reviews. Cancer (2023) Vol. 23, Iss. 4, pp. 193-215
Closed Access | Times Cited: 137
DNA repair defects in cancer and therapeutic opportunities
Jessica L. Hopkins, Li Lan, Lee Zou
Genes & Development (2022) Vol. 36, Iss. 5-6, pp. 278-293
Open Access | Times Cited: 118
Genomic instability, inflammatory signaling and response to cancer immunotherapy
Mengting Chen, Renske Linstra, Marcel A.T.M. van Vugt
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2021) Vol. 1877, Iss. 1, pp. 188661-188661
Open Access | Times Cited: 117
The DNA Damage Response and Inflammation in Cancer
Vanessa Klapp, Beatriz Álvarez-Abril, Giuseppe Leuzzi, et al.
Cancer Discovery (2023) Vol. 13, Iss. 7, pp. 1521-1545
Open Access | Times Cited: 54
The complementarity of DDR, nucleic acids and anti-tumour immunity
Anand Kornepati, Cody M. Rogers, Patrick Sung, et al.
Nature (2023) Vol. 619, Iss. 7970, pp. 475-486
Closed Access | Times Cited: 46
Gender-Specific Genetic Predisposition to Breast Cancer: BRCA Genes and Beyond
Virginia Valentini, Agostino Bucalo, Giulia Conti, et al.
Cancers (2024) Vol. 16, Iss. 3, pp. 579-579
Open Access | Times Cited: 16
Predictive biomarkers for response to immune checkpoint inhibition
Benjamin Shum, James Larkin, Samra Turajlic
Seminars in Cancer Biology (2021) Vol. 79, pp. 4-17
Closed Access | Times Cited: 95
Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial
Thomas Powles, Srikala S. Sridhar, Yohann Loriot, et al.
Nature Medicine (2021) Vol. 27, Iss. 12, pp. 2200-2211
Closed Access | Times Cited: 95
Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial
Patrick M. Forde, Valsamo Anagnostou, Zhuoxin Sun, et al.
Nature Medicine (2021) Vol. 27, Iss. 11, pp. 1910-1920
Open Access | Times Cited: 87
Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity
S.Y. Cindy Yang, Scott Lien, Ben X. Wang, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 84
Mapping molecular subtype specific alterations in breast cancer brain metastases identifies clinically relevant vulnerabilities
Nicola Cosgrove, Damir Varešlija, Stephen Keelan, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 59
BRCA mutated pancreatic cancer: A change is coming
Michael N. Rosen, Rachel Goodwin, Michael M. Vickers
World Journal of Gastroenterology (2021) Vol. 27, Iss. 17, pp. 1943-1958
Open Access | Times Cited: 56
Nivolumab plus ipilimumab, with or without enzalutamide, in AR‐V7‐expressing metastatic castration‐resistant prostate cancer: A phase‐2 nonrandomized clinical trial
Eugene Shenderov, Karim Boudadi, Wei Fu, et al.
The Prostate (2021) Vol. 81, Iss. 6, pp. 326-338
Open Access | Times Cited: 55
Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity
Xiaoxiao Ma, Nadeem Riaz, Robert M. Samstein, et al.
Nature Genetics (2022) Vol. 54, Iss. 7, pp. 996-1012
Open Access | Times Cited: 54
BRCA mutational status shapes the stromal microenvironment of pancreatic cancer linking clusterin expression in cancer associated fibroblasts with HSF1 signaling
Lee Shaashua, Aviad Ben‐Shmuel, Meirav Pevsner‐Fischer, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 45
Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA–Associated Pancreatic Cancer in the Clinical and Preclinical Setting
Chani Stossel, Maria Raitses‐Gurevich, Dikla Atias, et al.
Cancer Discovery (2023) Vol. 13, Iss. 8, pp. 1826-1843
Open Access | Times Cited: 28
Immunogenomic analysis of human brain metastases reveals diverse immune landscapes across genetically distinct tumors
Ángel F. Álvarez-Prado, Roeltje R. Maas, Klara Soukup, et al.
Cell Reports Medicine (2023) Vol. 4, Iss. 1, pp. 100900-100900
Open Access | Times Cited: 27
Genomic Profiling Reveals Germline Predisposition and Homologous Recombination Deficiency in Pancreatic Acinar Cell Carcinoma
Diana Mandelker, Antonio Marra, Binbin Zheng-Lin, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 33, pp. 5151-5162
Open Access | Times Cited: 23
Page 1 - Next Page

Scroll to top